US/UK/Canada

Share

Quotes

We are pleased to have taken a significant step in the development of improved therapeutic options in ulcerative colitis treatment.
Nigel Titford CEO BioGaia Pharma
We believe that BGP345A has potential to provide a novel and effective approach to restoring gut motility where treatment is currently suboptimal. The initiation of patient enrolment is an important step in our development and confirms our commitment to develop novel live-microbial based solutions in areas of medical need.
Nigel Titford CEO of BioGaia Pharma
Pick a time period -
Tags ( Active)

BioGaia Pharma wins the jury’s choice award at Medicon Valley Microbiome Pitch Day

BioGaia Pharma participated in the Medicon Valley Microbiome Pitch Day, an event to showcase research projects and startups in the microbiome field looking for collaboration or investment.On September 27, nine startups were invited to pitch themselves in front of an esteemed investor jury. BioGaia Pharma and Myco Biotix were the two startups selected for their strong science, experienced teams, and clear business models. “I want to thank Medicon Valley Alliance, for arranging this important event to drive innovation forward and for bringing together startups in the microbiome field to

BioGaia Pharma announces First Patient Enrolled in Phase I Clinical Study Evaluating BGP014 in mild to moderate ulcerative colitis (AUCH-1).

BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021.  Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into AUCH-1 in February 2022.“We are pleased to have taken a significant step in the development of improved therapeutic options in ulcerative colitis treatment,” said Nigel Titford CEO of BioGaia Pharma. BGP014 is targeted to Ulcerative Colitis (UC). UC is a debilitating condition characterised by chronic inflammation in the intestinal

BioGaia Pharma announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)

BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into OIC-1 in January 2022.BGP345A looks to treat constipation in patients receiving opioid therapy for prescribed pain treatment. Opioids are an essential option for chronic pain, primarily back pain, rheumatism or post-operative pain, where non-opioid multimodal drugs or physical therapy are not providing relief. Opioid use can lead to a

BioGaia Pharma secures approval for two clinical trials for its pharmaceutical candidates

BioGaia Pharma has received formal approval from relevant authorities to proceed with both of its planned clinical trials. The trials are the next phase in the development of BioGaia Pharma’s two pharmaceutical product candidates. The biologics both contain a single strain live microbial as API. Recruitment will start during late 2021.The first program BGP014 is for Ulcerative Colitis (UC). UC is a debilitating condition characterised by chronic inflammation in the intestinal tract affecting roughly 2,5 million patients in Europe and the US alone. There is no cure for UC and patients need

There are no items matching the current filter
There are no more items matching the current filter
Back to top